Stenhem Mikael, Ortqvist Ake, Ringberg Håkan, Larsson Leif, Olsson-Liljequist Barbro, Haeggman Sara, Ekdahl Karl
Department of Epidemiology, Swedish Institute for Infectious Disease Control, Karolinska Institutet, Solna, Sweden.
BMC Infect Dis. 2006 Feb 21;6:30. doi: 10.1186/1471-2334-6-30.
The occurrence of methicillin-resistant Staphylococcus aureus (MRSA) has gradually become more frequent in most countries of the world. Sweden has remained one of few exceptions to the high occurrence of MRSA in many other countries. During the late 1990s, Sweden experienced a large health-care associated outbreak which with resolute efforts was overcome. Subsequently, MRSA was made a notifiable diagnosis in Sweden in 2000.
From the start of being a notifiable disease in January 2000, the Swedish Institute for Infectious Disease Control (SMI) initiated an active surveillance of MRSA.
The number of reported MRSA-cases in Sweden increased from 325 cases in 2000 to 544 in 2003, corresponding to an overall increase in incidence from 3.7 to 6.1 per 100,000 inhabitants. Twenty five per cent of the cases were infected abroad. The domestic cases were predominantly found through cultures taken on clinical indication and the cases infected abroad through screening. There were considerable regional differences in MRSA-incidence and age-distribution of cases.
The MRSA incidence in Sweden increased over the years 2000-2003. Sweden now poises on the rim of the same development that was seen in the United Kingdom some ten years ago. A quarter of the cases were infected abroad, reflecting that international transmission is now increasingly important in a low-endemic setting. To remain in this favourable situation, stepped up measures will be needed, to identify imported cases, to control domestic outbreaks and to prevent transmission within the health-care sector.
耐甲氧西林金黄色葡萄球菌(MRSA)在世界上大多数国家的出现频率已逐渐增加。瑞典仍然是许多其他国家中耐甲氧西林金黄色葡萄球菌高发病率的少数例外之一。在20世纪90年代后期,瑞典经历了一次大规模的医疗保健相关疫情,通过坚定的努力得以克服。随后,耐甲氧西林金黄色葡萄球菌在2000年成为瑞典的法定报告诊断疾病。
自2000年1月成为法定报告疾病起,瑞典传染病控制研究所(SMI)启动了对耐甲氧西林金黄色葡萄球菌的主动监测。
瑞典报告的耐甲氧西林金黄色葡萄球菌病例数从2000年的325例增加到2003年的544例,相当于发病率从每10万居民3.7例总体增加到6.1例。25%的病例是在国外感染的。国内病例主要通过根据临床指征采集的培养物发现,国外感染的病例则通过筛查发现。耐甲氧西林金黄色葡萄球菌发病率和病例的年龄分布存在相当大的地区差异。
2000 - 2003年期间瑞典的耐甲氧西林金黄色葡萄球菌发病率有所上升。瑞典现在正处于大约十年前在英国所看到的相同发展边缘。四分之一的病例是在国外感染的,这反映出在低流行情况下国际传播现在越来越重要。为了保持这种有利形势,将需要加强措施,以识别输入性病例、控制国内疫情并防止在医疗保健部门内传播。